Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP1503 and Pembrolizumab in Advanced Melanoma
NCT03595683Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Oct 2018
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of edp1503 in melanoma, sponsored by University of Chicago. Started Oct 2018; status: terminated.
02
Drugs
edp1503
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03595683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595683.